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ABSTRACT
Peptic ulcer is a clearly marginated ulceration in mucosal membran that can penetrate until muscularis
layer and resulted from imbalance between aggressive factor (gastric acid and pepsin) and defensive factor
(gastric mucous, bicarbonate and prostaglandin, mucosal blood flow, and cell replacement). Factors that
can act as aggressive factor include H. pylori, NSAID, and smoking. Duodenal ulcer is frequently associ-
ated with H. pylori, in which Helicobacter pylori is found in 95 - 100% of duodenal ulcer patients..
It was reported, a 39 years old female patient with cirrhosis hepatis who suffered from melena in which
endoscopic examination revealed duodenal ulcer as a source of bleeding.There was no H. pylori, based on
serologic examination (IgG antiHP) and culture. The ulcer is suspected caused by  NSAID based on history
of using traditional medicine that may contain NSAID. Treatment with proton pump inhibitor and sucralfate
can heal the ulcer after two week treatment.
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INTRODUCTION
Peptic ulcer is a clearly marginated ulceration of
mucosal membrane that extend through the muscularis
mucosae, and result from an imbalance between aggres-
sive and defensive factor. Helicobacter pylori associ-
ated frequently with duodenal ulcer. Beside H. pylori,
there are many factor that can cause the duodenal ul-
cer.1,2
Liver cirrhosis is characterized by a reduction in func-
tional tissue and by disorganization of lobular and vascu-
lar architecture leading to parenchymal dysfunction and
portal hypertension as the result of chronic wound heal-
ing in the liver following chronic damage.3,4
It will be reported, a female patient with liver cirrho-
sis and non-Hp duodenal ulcer that may be a relatively
rare case we found.
CASE REPORT
A 39 years old female patient worked in plywood
factory in East Kalimantan enterred the hospital with
chief complaint dark colour stool. She suffered from dark
colour stool three times since one day before admission.
Her abdomen enlarged gradually since one year before
admission, associated with anorexia and full sensation,
and yellowish eyes. There was skin hyperpigmentation
and her hair was easy to fall since six month before
admission. She frequently took many kind of traditional
medicine to treat herself, but she didn’t know what the
names of those medicine are. She didn’t get improve-
ment of her condition.
From physical examination, the patient look moder-
ately ill, fully consciouss, body height 155 cm, body weight
46 kg, body mass index 19.02 kg/m2, blood pressure 100/
70 mmHg, pulse rate 108 x/mnt, respiratory rate 24 x/
mnt, conjunctiva look anemic, sclera look icteric, hyper-
pigmentation of skin. No abnormality on chest examina-
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tion. There was abdominal enlargement with undulation
and shifting dullness. There was ankle edema on both
leg.
The results of laboratory examination included: Hb
7.5 gr/dl, leukocyt 8300/uL, ESR 24 mm/hour, thrombocyt
67000 /uL, blood smear: erythrocyt hypochrom
mycrocyter, fasting blood glucose 60 mg/dl, postprandial
blood glucose 180 mg/dl, ureum 65.5 mg/dl, creatinin 1.19
mg/dl, total bilirubin 5.47 mg/dl, direct bilirubin 0.08 mg/
dl, indirect bilirubin 5.39 mg/dl, SGOT 41 mU/ml, SGPT
30 mU/ml, total protein 4.8 gr/dl, albumin 1.8 gr/dl, globulin
3.0 gr/dl, HbsAg (MEIA): (+) abs 1077.7, cut off  6.0.
IgG anti H. pylori: negative. There was no colony of H.
pylori from culture.  Ascites fluid analyse: straw coloured,
erythrocyt 50/cmm with 100% crenation, leukocyt  100/
cmm with 40% PMN and 60% MN, Rivalta test nega-
tive, protein 430 mg/dl, glucose 97 mg/dl. Endoscopic
examination showed esophageal varices grade II/III
without bleeding sign, multiple ulcer in duodenum with
bleeding. Histopathologic examination showed ulceration
of duodenal mucosa with shortening and widening of villi
and mononuclear inflammatory cells infiltration; this find-
ings usually are found in duodenal ulcer. There was no
malignancy in this specimen. Ultrasonography showed
the features of liver cirrhosis and ascites.
Treatment included bed rest, soft diet with high calo-
rie and high protein and salt restriction (2 gr NaCl),
lansoprazole 1x30 mg/day, sucralfate 4x1 gr/day,
spironolacton 1x100 mg/day, lactulose 4x30 ml/day,
lavement every 12 hours. In the third day, there was no
melena anymore and then lavement was stopped, while
other treatment was continued. After two week treat-
ment, reendoscopic examination showed the disappear-
ance of duodenal ulcer. Finely, the treatment was con-
tinued with spironolacton 1x100 mg/day, propranolol 2x10
mg/day, lansoprazole 1x30 mg/day, and sucralfate 4x1gr/
day.
DISCUSSION
Peptic ulcer disease is thought to result from an im-
balance between aggressive factors, especially gastric
acid and pepsin, and protective factors, including gastric
mucus, bicarbonate, prostaglandin, mucosal blood flow,
and epithel cell replacement. H. pylori, NSAIDs and
smoking can act as aggressive factors.1,2 H. pylori is
found in 95-100% patients with duodenal ulcer.1 Endos-
copy is a sensitive, spesific, and safe method for the
diagnosis of peptic ulcer disease that is followed with
biopsy for histopathologic examination.2 Liver cirrhosis
represents chronic wound healing in the liver
(fibrinogenesis) following chronic damage caused by
many factors include viral agents (e.g., HBV and HCV),
toxins, drugs, metabolic diseases (hemochromatosis, al-
pha-1 antitrypsin deficiency), autoimmune disease, and
biliary disease. The diagnosis of cirrhosis is made by
evaluation of clinical signs, laboratory studies of liver
function, ultrasonography and laparoscopy-liver biopsy.
Laparoscopy is the gold standard for the investigation of
liver cirrhosis that allows both macroscopic and micro-
scopic (histopathologic) examination by directed liver
biopsy.4
In this case, the diagnosis of liver cirrhosis was based
on the result of abdominal ultrasonography that shows
the features of liver cirrhosis and ascites. This finding
was supported by clinical and laboratory evaluation that
showed the features of chronic liver disease with the
suspected causative factor is hepatitis B virus infection.
The diagnosis of duodenal ulcer was based on the result
of endoscopy that show multiple ulcer with bleeding in
duodenum, with the result of histopathologic examina-
tion reveal the features of duodenal ulcer. There was no
Helicobacter pylori from serologic examination (IgG anti
Hp) and culture. Therefore, the patient is diagnosed as
liver cirrhosis with non-Hp duodenal ulcer. The suspected
causative agent of this ulcer is NSAID, based on history
of using traditional medicine that may contain NSAID.
NSAIDs are directly toxic to the gastric mucosa, and
they deplete protective endogenous mucosal prostaglan-
dins by inhibiting prostaglandin synthesis. They reduce
gastric mucus secretion, gastric and duodenal bicarbon-
ate secretion, increase gastric acid secretion, and also
impair epithelial cell replacement. Some drugs that can
treat peptic ulcer include antacids, antisecretory drug (H2-
reseptor antagonis, proton pump inhibitor, anticholinergic
agents, and prostaglandin), and cytoprotective drug
(sucralfate). H2-receptor antagonis and proton pump in-
hibitor (PPI) can effectively prevent and heal NSAID-
induced ulcer. PPI may heal ulcer within 2-4 week treat-
ment. PPI may accelerate the healing of such ulcers
even if NSAID use is continued.1,2,5
In this case, the patient was treated with lansoprazole
1x30 mg/day as PPI that inhibit acid secretion, sucralfate
4x1gr/day as cytoprotective drug that protect gastric
mucosa. PPI is an inhibitor of acid secretion that more
potent than H2-receptor antagonis and effective in heal-
ing NSAID-induced ulcers, while sucralfate can protect
ulcer and mucosa from gastric acid, can bind bile acid,
increase endogenous tissue prostaglandin, and may bind
epidermal growth factors and present them to the ulcer,
thereby increasing mucosal defense.1,2,5
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Treatment of liver cirrhosis includes: treatment of the
underlying disease, administration of antifibrotic drugs,
prevention and treatment of complications (portal hy-
pertension, ascites, hepatic encephalopathy). In cases
of HBV and HCV, giving antiviral agent in compensated
liver cirrhosis may be effective in eliminating HBV and
HCV, but it should not be used routinely in patients with
liver cirrhosis because decompensation and severe side
effects may occur.4 Therefore, in this patient who have
decompensated liver cirrhosis, such treatment was not
given. The use of antifibrotic drugs which can stop fi-
brosis to treat cirrhosis is still experimental and not yet
of clinical relevance. Beta-blockers and nitrates are use-
ful in reducing portal hypertension and preventing va-
riceal bleeding.4,6 In this case, propranolol was given to
the patient in order to reduce portal hypertension. The
treatment of ascites should be started by instituting a
low sodium (max 3 gr NaCl/day), low fluid intake (1-1,5
liter/day), albumin substitution, and diuretic therapy
(spironolactone, xipamide).  In pronounced ascites, the
treatment can be done by paracentesis with concomi-
tant albumin substitution.4,6 The treatment of ascites for
this patient included low salt diet (2 gr NaCl), potassium
sparing diuretic (spironolacton 100mg/day) to enhance
diuresis, whereas albumin substitution cannot be given
because of high cost.
Gastrointestinal bleeding can become a precipitating
factor of hepatic encephalopathy. Blood has to be evacu-
ated from the bowel, and the bleeding has to be stopped.
Lactulose can act as laxative agent, supress production
and absorption of ammonia in the bowel 4,6. In this case,
the patient suffered from melena that caused by bleed-
ing from duodenal ulcer. The drug that treat the ulcer
can stop the bleeding. Gastric Lavage every 12 hours
was performed to evacuated blood from the bowel, and
lactulose could prevent hepatic encephalopathy. The
treatment of duodenal ulcer has succesfully treated and
made healing of the ulcer after two week treatment in
which re-endoscopic examination showed the disappear-
ance of the ulcer.
CONCLUSION
A case was reported, a 39 years old female patient
with liver cirrhosis had multiple ulcer in duodenum, based
on endoscopic examination. Most of duodenal ulcer is
associated with Helicobacter pylori as a cusative agent,
but in this case, there was no H. pylori on serologic ex-
amination and culture. The suspected causative agent is
NSAID, based on history of using traditional medicine
that may contain NSAID.
Treatment of duodenal ulcer included proton pump
inhibitor and cytoprotective drug that can make ulcer
healing after two week treatment, whereas the treat-
ment of cirrhosis was directed to reduce ascites by us-
ing potasium sparring diuretic, and reduce portal hyper-
tension by using beta-blocker.
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